Elo Mutual Pension Insurance Co Has $9.49 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Elo Mutual Pension Insurance Co lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,555 shares of the pharmaceutical company's stock after selling 970 shares during the quarter. Elo Mutual Pension Insurance Co's holdings in Vertex Pharmaceuticals were worth $9,486,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in VRTX. Larson Financial Group LLC raised its stake in shares of Vertex Pharmaceuticals by 21.9% during the 3rd quarter. Larson Financial Group LLC now owns 417 shares of the pharmaceutical company's stock worth $194,000 after purchasing an additional 75 shares in the last quarter. Truvestments Capital LLC acquired a new position in Vertex Pharmaceuticals in the third quarter worth approximately $35,000. Qsemble Capital Management LP raised its position in Vertex Pharmaceuticals by 68.3% during the third quarter. Qsemble Capital Management LP now owns 1,264 shares of the pharmaceutical company's stock valued at $588,000 after acquiring an additional 513 shares in the last quarter. D.A. Davidson & CO. lifted its stake in Vertex Pharmaceuticals by 12.6% in the third quarter. D.A. Davidson & CO. now owns 5,475 shares of the pharmaceutical company's stock valued at $2,546,000 after acquiring an additional 611 shares during the last quarter. Finally, Baldwin Investment Management LLC grew its position in Vertex Pharmaceuticals by 1.1% in the third quarter. Baldwin Investment Management LLC now owns 11,891 shares of the pharmaceutical company's stock worth $5,530,000 after acquiring an additional 135 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Scotiabank lifted their price objective on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a "sector perform" rating in a research note on Tuesday, February 11th. Stifel Nicolaus upped their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research note on Monday, December 16th. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Barclays upped their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Finally, StockNews.com raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $508.65.

Vertex Pharmaceuticals Stock Performance

VRTX traded down $11.66 during trading on Monday, reaching $481.03. 636,245 shares of the company's stock were exchanged, compared to its average volume of 1,273,134. The company has a market capitalization of $123.52 billion, a P/E ratio of -219.91, a PEG ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $476.45 and a 200 day moving average price of $463.64. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,315 shares of company stock worth $2,121,012. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.